ByTrending Posts
Takeda Announces Positive Phase III Results for AI-Discovered…
Tokyo, Japan – December 19, 2025 – Takeda Pharmaceutical Company Limited today announced successful results from two Phase…
Geneva inaugurates first artificial intelligence health hub at…
GENEVA, Dec. 8, 2025 — Geneva has officially inaugurated its first artificial intelligence health hub at Campus Biotech,…
Cradle AI-powered protein engineering platform serving six of…
AMSTERDAM and ZURICH, Dec. 16, 2025 — Cradle, an enterprise-grade AI software platform for protein engineering, today announced…
Adaptive Biotechnologies and Pfizer Announce Strategic Research Collaboration…
A target discovery agreement to identify disease-specific T-cell receptors (TCRs) in rheumatoid arthritis. A data licensing agreement to…
Is Merck and Nvidia’s KERMT Model the Breakthrough…
Key Highlights / Executive Takeaways: • Merck and Nvidia introduce KERMT, a next-generation small-molecule AI model trained on…
Will LabGenius Therapeutics and Sanofi’s Second AI-Powered Alliance…
Key Highlights / Executive Takeaways: • Expanded collaboration deepens trust between LabGenius Therapeutics and Sanofi, reinforcing AI/ML as…
Can Phare Bio and Basilea’s AI-Driven Alliance Redefine…
Executive Takeaways: • First-of-its-kind partnership aligns AI-driven antibiotic design directly with patient-centric target product profiles, setting a new…
FDA Qualifies First AI Drug Development Tool, Will…
The U.S. Food and Drug Administration (FDA) has qualified AIM-NASH, the first AI-based tool designed to assist doctors…
How Novartis and Relation Therapeutics’ $1.7 Billion AI…
Key Highlights: • AI-driven, patient-derived target discovery emerges as a new gold standard for reducing late-stage clinical failures•…
Trending Posts
Latest Stories
Is GSK Buying Its Way Past the Patent Cliff? $2.2 Billion Rapt Therapeutics Deal Signals Pipeline Reset
January 2026 Executive Summary GSK has agreed to acquire Rapt Therapeutics, a U.S.-based biotech focused…
Is AI Poised to Replace the Traditional Drug Discovery Lab? Nvidia CEO Signals a Paradigm Shift in Pharma R&D
23 January 2026 Executive Summary Nvidia CEO Jensen Huang has underscored the transformative potential of…
Is Short-Term Cost Control Undermining Long-Term Innovation? Novartis Calls for Structural Reform in Global Healthcare
23 January 2026 Executive Summary Novartis has issued a call for structural reform in global…
Is Regional Distribution Becoming a Strategic Lever for Big Pharma? Novartis Expands European Reach Through Malta Partnership
23 January 2026 Executive Summary Novartis Pharma Services AG has entered into a strategic distribution…
Gallery
